TINO: T Cells in the Nose of Older Adults

L

Leiden University Medical Center (LUMC)

Status

Enrolling

Conditions

Aging
Respiratory Tract Infections

Study type

Observational

Funder types

Other

Identifiers

NCT06039527
NL77841.058.21 (Registry Identifier)
P21.066

Details and patient eligibility

About

Rationale: Individuals with advanced age are at a progressively increasing risk of acquiring lower respiratory tract infections. Besides calendar age, the degree of frailty also associates with increased susceptibility to pneumonia requiring hospitalization. How alterations in the mucosal immune system with advanced age predispose to infections remains unclear as access to relevant tissue samples is limited. With minimally-invasive nasal sampling methods, it was recently observed that in vital older adults, both CD4+ T cells and CD8+ T cells are selectively lost from the nasal mucosa. However, the exact phenotype, underlying mechanisms, key molecules and consequences of this have not yet been investigated. Objective: Elucidate the mechanisms underlying the loss of nasal T cells and characterize in depth the differences of T cells in young and older adults and associate this loss with susceptibility to infections. Study design: Prospective cohort study Study population: Participants will be recruited from 3 groups: * healthy young adults (18-30 years, n=50) * vital older adults (\>65 years, n=60) * frail elderly (\>65 years, n=60). This group includes individuals without a history of recurrent respiratory infections or with \>2 self-reported episodes of respiratory infection in the past year. Main study parameters/endpoints: Frequency of nasal CD8+ T cells in young adults and frail older adults. Secondary study parameters/endpoints: * Phenotype (subsets, activation status), functionality, transcriptomic state, clonality and frequency of nasal and blood T cell populations * Stability of T cells and other immune parameters, as described for main study parameter, during a second sample after 3 months. * Analysis of other immune populations as for main study parameter * Concentration of nasal and systemic factors (e.g. cytokines and metabolites) and their association with T cells and other immune populations * Respiratory tract microbiota profiles and presence of asymptomatic viral infections and their association with T cells and other immune parameters * Chronological and biological age, sex, and other immunologically relevant parameters with T cell populations and other immune parameters * Alteration of T cell phenotype, during and following respiratory tract infections. Levels of antigen-specific T cells and other immune parameters in nose and blood post infection.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

•Adults able and willing to provide informed consent.

Specific inclusion criteria per group:

  • Young adults aged 18-30 years old
  • Healthy elderly aged >65 years old
  • Frail elderly >65 years old
  • Clinical Frailty score healthy elderly 1-3
  • Clinical Frailty score frail elderly >3
  • Self-reported respiratory tract infection in previous year healthy elderly 0-1
  • Self-reported respiratory tract infection in previous year frail elderly 0-1 or >1

Exclusion criteria

  • Incompetence to provide informed consent prior or during study
  • Current smoker or >40 pack year history
  • History of severe nose bleedings
  • Diagnosed with asthma, COPD or chronic rhinosinusitis
  • Use of inhalation corticosteroids or antibiotics in the past 6 weeks
  • Current use of anti-coagulants (to prevent nosebleeds). Platelet inhibitors like acetylsalicylzuur (Ascal) are allowed.
  • Respiratory tract infection or common cold in the past 2 weeks
  • Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency)
  • Life expectancy <28 days in the opinion of study physician
  • Vaccination in the 2 months prior to study start. A potential subject that is only excluded from participation based on a recent vaccination will be asked to re-participate 2 months post vaccination.

Trial design

170 participants in 3 patient groups

Young adults
Description:
N=50 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
Vital elderly
Description:
N=60 of this group No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset
Frail elderly
Description:
N=60 of this group. Half with recurring respiratory infections, and half without No intervention. Sampling at timepoint 0 and for 50% of the group another sample at 3 months If respiratory symptoms develop in the 3 months after timepoint 0, participants are invited to provide a NPS/OPS to identify causative agent, and if one is established, individuals are sampled 3 more times at months 1, 3 and 5 post symptom onset

Trial contacts and locations

1

Loading...

Central trial contact

Simon P Jochems, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems